Connection

Fernando Bozza to Virus Replication

Back to Details
This is a "connection" page, showing publications Fernando Bozza has written about Virus Replication.
Fernando Bozza
Connection Strength
0.070
Virus Replication
  1. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep. 2017 01 18; 7:40920.
    View in: PubMed
    Score: 0.036
  2. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators. PLoS Pathog. 2020 12; 16(12):e1009127.
    View in: PubMed
    Score: 0.012
  3. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. Antimicrob Agents Chemother. 2020 09 21; 64(10).
    View in: PubMed
    Score: 0.012
  4. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci Rep. 2017 08 25; 7(1):9409.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.